Cochrane · systematic review · CD010008
Topiramate for juvenile myoclonic epilepsy
Liu, J, Tai, Y-J, Wang, L-N · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTopiramate compared with placebo for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs placebo | RR 4 [1.08, 14.75] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs placebo | no estimate extracted | NR | No studies |
Topiramate compared with valproate for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) Topiramate vs valproate | RR 0.88 [0.67, 1.15] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs valproate | RR 1.22 [0.68, 2.21] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs valproate | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs valproate | RR 1.13 [0.61, 2.11] | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision |
Topiramate compared with placebo for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs placebo | RR 4 [1.08, 14.75] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs placebo | no estimate extracted | NR | No studies |
Topiramate compared with valproate for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) Topiramate vs valproate | RR 0.88 [0.67, 1.15] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs valproate | RR 1.22 [0.68, 2.21] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs valproate | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs valproate | RR 1.13 [0.61, 2.11] | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision |
Topiramate compared with placebo for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs placebo | RR 4 [1.08, 14.75] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs placebo | no estimate extracted | NR | No studies |
Topiramate compared with valproate for juvenile myoclonic epilepsy
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) Topiramate vs valproate | RR 0.88 [0.67, 1.15] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) Topiramate vs valproate | RR 1.22 [0.68, 2.21] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs Topiramate vs valproate | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free Topiramate vs valproate | RR 1.13 [0.61, 2.11] | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision |
Comparison
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) | RR 4 [1.08, 14.75] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free | no estimate extracted | NR | No studies |
Comparison
Population: people with juvenile myoclonic epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of responders (at least 50% seizure frequency reduction in myoclonic seizures) | RR 0.88 [0.67, 1.15] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of responders (at least 50% seizure frequency reduction in PGTCS) | RR 1.22 [0.68, 2.21] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced at least one AE and individual AEs | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants who were seizure‐free | RR 1.13 [0.61, 2.11] | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision |